The post Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance appeared on BitcoinEthereumNews.com. CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images) Getty Images Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all. Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features. Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for… The post Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance appeared on BitcoinEthereumNews.com. CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images) Getty Images Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all. Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features. Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for…

Generic Drugs Are The Physical Manifestation Of Lifesaving Abundance

2025/10/29 02:21

CHICAGO – JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world’s biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world’s top-selling drug. (Photo by Scott Olson/Getty Images)

Getty Images

Ludwig von Mises long ago observed that the notion of luxury is entirely historical. The previous truth is important to remember as Sens. Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) take aim at generic drugs. For the senators to question the safety and quality of generics whether produced stateside or overseas is for them to question the brilliant evolution of all market advances that ultimately expand access to goods formerly inaccessible to all but the richest of the rich, if at all.

Cars once driven by the very rich were rendered plentiful by Henry Ford given his desire to manufacture them for “the great multitude.” The first IBM mainframe computer in the 1960s fetched over $1 million dollars, only for visionaries like Michael Dell to become billionaires by virtue of mass-producing computers similarly available to “the great multitude.” In 1983, Motorola launched the first mobile phone for $3,995, while today we have supercomputers in our pockets that transmit calls for us, in addition to thousands of other features.

Which is why pharmaceutical advance is so important. No doubt politicians can and do blanch at the dollars expended on innovations meant to mitigate the horrors of cancer, heart disease, Alzheimer’s and countless other maladies, but the people invariably benefit. And this is true even if it’s similarly true that initial pharmaceutical leaps gift the very few very well to do with drugs not available to the broader population. We should cheer such an outcome, and for obvious reasons.

As the formerly inaccessible car, computer, and mobile phone make blindingly plain, the luxuries of the very rich foretell what we’ll all enjoy if markets are free. It’s that simple.

Which is the point of generic drugs. They’re brilliant pharmaceutical representations of what’s true in all walks of profit-motivated life. What’s expensive in the near-term, and as pharmaceutical companies recoup the enormous costs associated with funding their intrepid leaps, eventually is not.

All of which helps explain why 90 percent of pharmaceutical prescriptions filled are generic. It’s an essential progression.

Which is why pushback against Sens. Scott and Gillibrand is so necessary. For them to attack generic drugs, and in particular foreign-produced generics is for the senators to attack a progression that has long democratized access to life-enhancing and life-saving drugs. Worse, it’s an attack on the evolution of all market advances that are invariably an effect of globalized production.

At which point it’s quite simply odd that Scott would call into question the validity of the FDA’s inspections of foreign generics. The questioning implies an easy FDA that is belied by history, and that Republicans have long criticized as too stringent.

For now, healthcare and the drugs associated with it are frequently expensive. Which is the point. What’s great has to be initially expensive, but much more importantly, what’s inexpensive and accessible to all must initially be quite costly.

Thank goodness for the globalized production that eventually turns costly scarcity into abundance. Scott and Gillibrand should be thankful too, and retrieve legislation meant to suffocate the democratization of what improves life, and often saves it too.

Source: https://www.forbes.com/sites/johntamny/2025/10/28/generic-drugs-are-the-physical-manifestation-of-democratized-abundance/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

BetFury is at SBC Summit Lisbon 2025: Affiliate Growth in Focus

BetFury is at SBC Summit Lisbon 2025: Affiliate Growth in Focus

The post BetFury is at SBC Summit Lisbon 2025: Affiliate Growth in Focus appeared on BitcoinEthereumNews.com. Press Releases are sponsored content and not a part of Finbold’s editorial content. For a full disclaimer, please . Crypto assets/products can be highly risky. Never invest unless you’re prepared to lose all the money you invest. Curacao, Curacao, September 17th, 2025, Chainwire BetFury steps onto the stage of SBC Summit Lisbon 2025 — one of the key gatherings in the iGaming calendar. From 16 to 18 September, the platform showcases its brand strength, deepens affiliate connections, and outlines its plans for global expansion. BetFury continues to play a role in the evolving crypto and iGaming partnership landscape. BetFury’s Participation at SBC Summit The SBC Summit gathers over 25,000 delegates, including 6,000+ affiliates — the largest concentration of affiliate professionals in iGaming. For BetFury, this isn’t just visibility, it’s a strategic chance to present its Affiliate Program to the right audience. Face-to-face meetings, dedicated networking zones, and affiliate-focused sessions make Lisbon the ideal ground to build new partnerships and strengthen existing ones. BetFury Meets Affiliate Leaders at its Massive Stand BetFury arrives at the summit with a massive stand placed right in the center of the Affiliate zone. Designed as a true meeting hub, the stand combines large LED screens, a sleek interior, and the best coffee at the event — but its core mission goes far beyond style. Here, BetFury’s team welcomes partners and affiliates to discuss tailored collaborations, explore growth opportunities across multiple GEOs, and expand its global Affiliate Program. To make the experience even more engaging, the stand also hosts: Affiliate Lottery — a branded drum filled with exclusive offers and personalized deals for affiliates. Merch Kits — premium giveaways to boost brand recognition and leave visitors with a lasting conference memory. Besides, at SBC Summit Lisbon, attendees have a chance to meet the BetFury team along…
Share
BitcoinEthereumNews2025/09/18 01:20
Solana Treasury Firm Forward Industries Launches $1 Billion Buyback, Files SEC Resale Prospectus

Solana Treasury Firm Forward Industries Launches $1 Billion Buyback, Files SEC Resale Prospectus

Forward Industries, Inc. (NASDAQ: FORD) has moved to reinforce investor confidence with two major corporate actions. The Solana-focused treasury firm announced a new $1 billion share repurchase authorization and confirmed the filing of a resale prospectus supplement with the U.S. Securities and Exchange Commission. These decisions reflect a strong strategic conviction as the company continues to expand its Solana-related operations and capital market initiatives.Share Buyback Reflects Long-Term ConfidenceAs per the issued press release, the Board of Directors approved the $1 billion buyback program on November 3, 2025. The plan allows Forward Industries to purchase its common stock through open-market transactions, private deals, or accelerated share repurchases. According to the company, the program provides flexibility to act on favorable market conditions while ensuring compliance with SEC Rule 10b-18.Chairman Kyle Samani stated, “Today’s announcement reflects our confidence in both Forward Industries’ differentiated strategy and the underlying strength of Solana’s ecosystem.” He added that the initiative underscores the company’s long-term view, saying it “gives us flexibility to return capital to shareholders when we believe our stock trades below intrinsic value.”The program will remain active until September 30, 2027, unless modified or terminated earlier. The company indicated that the timing and volume of repurchases would depend on share price, liquidity, and overall market conditions.Filing of Resale Prospectus and Market ImplicationsIn tandem, Forward Industries filed a resale prospectus supplement to register certain shares from its September 2025 private placement. The filing permits selling shareholders to trade those securities at their discretion. The company clarified that it will not receive any proceeds from those resales.Market observers noted that the timing of both actions signals confidence in the firm’s balance sheet and the Solana ecosystem’s potential for institutional adoption. The buyback authorization, alongside the resale filing, positions Forward Industries to stabilize its stock performance while maintaining strategic liquidity.Market Reaction and Price OutlookSource: Google FinanceDespite the strategic developments, the company’s stock fell 24.75%as of press time, closing at $10.52. The decline from its $13.98 opening price reflected strong selling pressure and short-term investor caution. Analysts suggest that traders may have responded to profit-taking following recent gains or uncertainty surrounding the resale filing. Unless the price stabilizes above $11, further downside toward the $10 psychological support level remains possible.
Share
Coinstats2025/11/05 04:53